NEW YORK, NY / ACCESS Newswire / February 9, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Novo Nordisk’s haemophilia A therapy Mim8 stopped bleeding completely in 74.3% of children in a Phase III trial. The ...

Novo Nordisk's hemophilia A drug Mim8 shows success in pediatric trial, Mim8 could compete with Roche's Hemlibra, with plans ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

NVO Investors with Losses Encouraged to Contact the FirmSan Francisco, California--(Newsfile Corp. - February 6, 2025) - Novo Nordisk A/S (NYSE: ...

Trademark prosecution data reveals how the rival healthcare companies are ensuring exclusivity internationally for their ...

Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a ...

A new study found that pa­tients tak­ing GLP-1s to treat type 2 di­a­betes have a low­er risk of de­vel­op­ing Alzheimer’s dis­ease, po­ten­tial­ly open­ing the door … ...

Novo Nordisk has announced topline results from the phase 3b trial STEP UP, which investigated the effects of two doses of Wegovy (semaglutide) in over 1,400 patients over the course of 72 weeks. Both ...

Bernard Arnault is once again in charge of Europe's most valuable company. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...